Phillip Brian Smith
8
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
12.5%
1 terminated/withdrawn out of 8 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
57%
4 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)
Role: lead
PK Study With Pantoprazole in Obese Children and Adolescents
Role: lead
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
Role: lead
Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates
Role: lead
Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease
Role: lead
An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates
Role: lead
Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
Role: lead
Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants
Role: lead
All 8 trials loaded